In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...

Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...

The VOR X RWY 10 at TNCM is incorrectly read by the FMC and incorrectly displayed - NAV mode cannot be used to fly approach. Programme the TNCM VOR X approach to TNCM through PJM. When comparing ...

Vor Biopharma's estimated fair value is US$15.10 based on 2 Stage Free Cash Flow to Equity Vor Biopharma is estimated to be 49% undervalued based on current share price of US$7.68 Our fair value ...

Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share. The gross proceeds from the offering are expected to be $100 million. In ...

Although design thinking is a common approach in the business community, its use for guiding development and adaptation processes is not yet common practice in the context of digital mental health.

I love being a licensed private pilot. As you may have seen from other videos, I am starting my instrument rating training. I really believe that I will be a much safer pilot when I get my IFR or ...

FRIDAY: A customer flew in from Lubbock for a couple of VOR approaches, then back in his Piper Cherokee 180. Mark Parish flew locally in his Cessna 182 Skylane. Med-Trans flew over to Covenant Health ...

Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor’s new-look C-suite.

The Correctness-by-Construction tutorial focuses on a structured programming approach for correct software development. Besides functional correctness, also non-functional properties such as security ...

Vor Bio grants CEO Jean-Paul Kress an option to purchase 83.3 million shares at $0.89, vesting over four years. Vor Bio, a biotechnology company specializing in autoimmune disease treatments, ...